Literature DB >> 16872438

Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2.

Shih-Sung Chuang1, Wan-Ting Huang, Pin-Pen Hsieh, Hui-Hwa Tseng, Elias Campo, Dolors Colomer, Hongtao Ye, Chin-Li Lu, Hui-Mei Chang, Chi-Yi Cho, Shih-Hung Huang, Yin-Che Lu, Jiann-Der Wu.   

Abstract

Mantle cell lymphoma (MCL) is a rare B-cell lymphoma that has never been characterized in Taiwan. The purpose of the present paper was to retrospectively identify 21 cases in male patients, with a median age of 61, involving lymph node (91%), marrow (71%), and peripheral blood (23%). Eighteen (86%) were in stages III/IV with 1 and 5 year survival rates of 78% and 17%, respectively. Mixed nodular and diffuse pattern (45%) was most common while interstitial pattern (92%) predominated in marrow. Eighteen (86%) were of classical morphology, two were pleomorphic and one was blastic. The tumors expressed IgM and bcl-2 (100%), cyclin D1 (95%), CD5 (86%), CD43 and IgD (62%), CD52 (60%), and bcl-6 (5%). Ki-67 index>or=30% (P=0.1834) was associated with a trend toward poorer survival while p21, p27, or p53 expression was not statistically significant for survival. Real-time polymerase chain reaction for cyclin D1 (CCND1) gene mRNA expression showed high levels in nine cyclin D1-positive patients and a low level in the single cyclin D1-negative patient. The latter patient was cyclin D2 positive and negative for immunoglubuin heavy chain gene and CCND1 gene translocation by locus-specific interphase fluorescent in situ hybridization. In conclusion, it is confirmed that the usual morphological variants and aberrant immunophenotype of MCL in the West occur in Taiwan and that this disease carries a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16872438     DOI: 10.1111/j.1440-1827.2006.01986.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  10 in total

1.  Chemotherapy for mantle cell lymphoma.

Authors:  R Sinharay
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

2.  SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.

Authors:  Ana Mozos; Cristina Royo; Elena Hartmann; Daphne De Jong; Cristina Baró; Alexandra Valera; Kai Fu; Dennis D Weisenburger; Jan Delabie; Shih-Sung Chuang; Elaine S Jaffe; Carmen Ruiz-Marcellan; Sandeep Dave; Lisa Rimsza; Rita Braziel; Randy D Gascoyne; Francisco Solé; Armando López-Guillermo; Dolors Colomer; Louis M Staudt; Andreas Rosenwald; German Ott; Pedro Jares; Elias Campo
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

3.  CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage.

Authors:  Arshia Soleimani; Alba Navarro; Delong Liu; Sarah E M Herman; Shih-Sung Chuang; Irma Slavutsky; Marina Narbaitz; Hana Safah; John Schmieg; John Lefante; Mark Roschewski; Wyndham H Wilson; Adrian Wiestner; Nakhle S Saba
Journal:  Leuk Lymphoma       Date:  2021-11-15

4.  Immunophenotypic profile and clinical characteristics in patients with advanced stage mantle cell lymphoma.

Authors:  M Todorovic; M Pavlovic; B Balint; N Kraguljac; B Mihaljevic; A Bogdanovic; I Elezovic; D Boskovic; M Colovic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

5.  Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma.

Authors:  Hanan Mohamed Mahmoud; Yasmin Nabil El-Sakhawy
Journal:  Hematol Rep       Date:  2011-11-16

6.  A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40.

Authors:  Jingtao Chen; Gerard Zurawski; Sandy Zurawski; Zhiqing Wang; Keiko Akagawa; Sangkon Oh; Ueno Hideki; Joseph Fay; Jacques Banchereau; Wenru Song; A Karolina Palucka
Journal:  J Hematol Oncol       Date:  2015-04-14       Impact factor: 17.388

7.  Quantitative flow cytometric evaluation of CD200, CD123, CD43 and CD52 as a tool for the differential diagnosis of mature B-cell neoplasms.

Authors:  Elissandra Machado Arlindo; Natália Aydos Marcondes; Flavo Beno Fernandes; Gustavo Adolpho Moreira Faulhaber
Journal:  Rev Bras Hematol Hemoter       Date:  2017-05-29

8.  Immunophenotyping of chronic B-cell neoplasms: flow cytometry versus immunohistochemistry.

Authors:  Afaf Abdel-Aziz Abdel-Ghafar; Manal Ahmed Shams El Din El Telbany; Hanan Mohamed Mahmoud; Yasmin Nabil El-Sakhawy
Journal:  Hematol Rep       Date:  2012-02-06

9.  Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma.

Authors:  Jie Jin; Rumiko Okamoto; Sung-Soo Yoon; Lee-Yung Shih; Jun Zhu; Ting Liu; Xiaonan Hong; Lixia Pei; Brendan Rooney; Helgi van de Velde; Huiqiang Huang
Journal:  Onco Targets Ther       Date:  2018-07-06       Impact factor: 4.147

Review 10.  Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group.

Authors:  Dok Hyun Yoon; Junning Cao; Tsai-Yun Chen; Koji Izutsu; Seok Jin Kim; Yok Lam Kwong; Tong Yu Lin; Lim Soon Thye; Bing Xu; Deok Hwan Yang; Won Seog Kim
Journal:  J Hematol Oncol       Date:  2020-03-17       Impact factor: 17.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.